Tibet Duo Rui Pharmaceutical Co., Ltd. (SHE:301075)
81.45
+0.74 (0.92%)
Apr 29, 2026, 4:00 PM EDT
SHE:301075 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 85.28 | 262.13 | 405.27 | 425.76 | 610.93 |
Trading Asset Securities | 20.04 | 141.68 | 77.57 | 80 | - |
Cash & Short-Term Investments | 105.32 | 403.81 | 482.84 | 505.76 | 610.93 |
Cash Growth | -73.92% | -16.37% | -4.53% | -17.21% | 484.67% |
Accounts Receivable | 87.89 | 107.94 | 85.51 | 92.3 | 100.33 |
Other Receivables | 17.09 | 19.55 | 11.2 | 7.88 | 2.28 |
Receivables | 104.98 | 127.49 | 96.7 | 100.18 | 102.6 |
Inventory | 83.54 | 45.85 | 33.13 | 32.77 | 9.82 |
Prepaid Expenses | - | 0 | 0.05 | 0.06 | 0.06 |
Other Current Assets | 35.23 | 53.61 | 36.23 | 8.66 | 5.64 |
Total Current Assets | 329.06 | 630.75 | 648.95 | 647.43 | 729.05 |
Property, Plant & Equipment | 694.53 | 652.8 | 209.8 | 110.68 | 103.41 |
Long-Term Investments | 110.99 | 108.18 | 155.36 | 112.62 | - |
Goodwill | 18.7 | 19.22 | 3.69 | - | - |
Other Intangible Assets | 76.64 | 78.48 | 34.19 | 21.24 | 16.85 |
Long-Term Deferred Tax Assets | 3.49 | 3.09 | 1.25 | 0.78 | 0.65 |
Long-Term Deferred Charges | 2.01 | 2.84 | 2.7 | 0.33 | 1.46 |
Other Long-Term Assets | 47.8 | 39.64 | 16.33 | 5.8 | - |
Total Assets | 1,283 | 1,535 | 1,072 | 898.87 | 851.42 |
Accounts Payable | 77.29 | 58.14 | 26.77 | 12.13 | 23.01 |
Accrued Expenses | 7.25 | 9 | 8.58 | 13.09 | 10.46 |
Short-Term Debt | 67.76 | 275.54 | 50.13 | 100.06 | 20 |
Current Portion of Long-Term Debt | 110.36 | 115.21 | 11.01 | - | - |
Current Portion of Leases | - | 3.03 | 0.6 | 0.29 | 0.48 |
Current Income Taxes Payable | 0.39 | 1.26 | 2.41 | 1.35 | 2.87 |
Current Unearned Revenue | 7.55 | 2.78 | 5.08 | 4.16 | 3.72 |
Other Current Liabilities | 171.55 | 44.41 | 24.6 | 13.49 | 2.25 |
Total Current Liabilities | 442.14 | 509.37 | 129.18 | 144.57 | 62.79 |
Long-Term Debt | 88.5 | 137.5 | 118.08 | - | - |
Long-Term Leases | 3.73 | 7.21 | 0.31 | 0.88 | - |
Long-Term Unearned Revenue | 105.02 | 106.9 | 2.12 | - | - |
Long-Term Deferred Tax Liabilities | 20.29 | 20.54 | 0.9 | - | - |
Total Liabilities | 659.67 | 781.52 | 250.59 | 145.45 | 62.79 |
Common Stock | 80 | 80 | 80 | 80 | 80 |
Additional Paid-In Capital | 506.89 | 506.94 | 509.22 | 509.5 | 520.5 |
Retained Earnings | 7.47 | 109.64 | 182.17 | 163.32 | 192.42 |
Treasury Stock | -20.99 | -20.99 | - | - | - |
Comprehensive Income & Other | 1.14 | 1.14 | 0.68 | -1.3 | - |
Total Common Equity | 574.51 | 676.73 | 772.06 | 751.53 | 792.92 |
Minority Interest | 49.03 | 76.74 | 49.61 | 1.89 | -4.28 |
Shareholders' Equity | 623.54 | 753.47 | 821.68 | 753.41 | 788.63 |
Total Liabilities & Equity | 1,283 | 1,535 | 1,072 | 898.87 | 851.42 |
Total Debt | 270.35 | 538.5 | 180.12 | 101.24 | 20.48 |
Net Cash (Debt) | -165.03 | -134.69 | 302.72 | 404.53 | 590.45 |
Net Cash Growth | - | - | -25.17% | -31.49% | 750.31% |
Net Cash Per Share | -2.08 | -1.70 | 3.85 | 5.13 | 9.05 |
Filing Date Shares Outstanding | 79.14 | 78.96 | 80 | 80 | 80 |
Total Common Shares Outstanding | 79.14 | 78.96 | 80 | 80 | 80 |
Working Capital | -113.07 | 121.38 | 519.77 | 502.85 | 666.26 |
Book Value Per Share | 7.26 | 8.57 | 9.65 | 9.39 | 9.91 |
Tangible Book Value | 479.17 | 579.04 | 734.19 | 730.29 | 776.06 |
Tangible Book Value Per Share | 6.05 | 7.33 | 9.18 | 9.13 | 9.70 |
Buildings | - | 506.96 | 167.55 | 117.46 | 103.71 |
Machinery | - | 251.45 | 126.2 | 63.47 | 60.37 |
Construction In Progress | - | 5.67 | 9.08 | 3.94 | 0.36 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.